前列腺癌 (PCa) 是全球男性中第二常见的癌症。 PCa的危险分层主要基于形态学检查。在这里，我们分析了来自 487 名中国 PCa 患者的 667 个肿瘤样本的蛋白质组，并通过 PulseDIA 质谱法表征了 9576 个蛋白质组。然后，我们开发了一个基于通路活性的分类器，涉及来自 7 个通路的 13 种蛋白质，并将 PCa 患者分为两个亚型，即 PPS1 和 PPS2。 PPS1具有增强的先天免疫功能，而PPS2具有抑制的先天免疫功能。该分类器在我们的队列中表现出与 PCa 进展的相关性，并通过两个已发表的转录组数据集进一步验证。值得注意的是，PPS2 与不良生化复发 (BCR)/无转移生存率显着相关（对数秩 P 值 < 0.05）。 PPS2还具有细胞增殖激活作用。我们的研究共同提出了一种新颖的基于通路活动的 PCa 分层方案。© 2023。作者。

Prostate cancer (PCa) is the second most common cancer in males worldwide. The risk stratification of PCa is mainly based on morphological examination. Here we analyzed the proteome of 667 tumor samples from 487 Chinese PCa patients and characterized 9576 protein groups by PulseDIA mass spectrometry. Then we developed a pathway activity-based classifier concerning 13 proteins from seven pathways, and dichotomized the PCa patients into two subtypes, namely PPS1 and PPS2. PPS1 is featured with enhanced innate immunity, while PPS2 with suppressed innate immunity. This classifier exhibited a correlation with PCa progression in our cohort and was further validated by two published transcriptome datasets. Notably, PPS2 was significantly correlated with poor biochemical recurrence (BCR)/metastasis-free survival (log-rank P-value < 0.05). The PPS2 was also featured with cell proliferation activation. Together, our study presents a novel pathway activity-based stratification scheme for PCa.© 2023. The Author(s).